Literature DB >> 25357108

Quantitative multiplexed detection of common pulmonary fungal pathogens by labeled primer polymerase chain reaction.

Zhengming Gu1, Daelynn R Buelow, Ruta Petraitiene, Vidmantas Petraitis, Thomas J Walsh, Randall T Hayden.   

Abstract

CONTEXT: Invasive fungal infections are an important cause of morbidity and mortality among immunocompromised patients.
OBJECTIVE: To design and evaluate a multiplexed assay aimed at quantitative detection and differentiation of the 5 molds that are most commonly responsible for pulmonary infections.
DESIGN: Using labeled primer polymerase chain reaction chemistry, an assay was designed to target the 5.8S and 28S ribosomal RNA genes of Aspergillus spp, Fusarium spp, Scedosporium spp, and members of the order Mucorales ( Rhizopus oryzae , Rhizopus microsporus, Cunninghamella bertholletiae, Mucor circinelloides, Lichtheimia corymbifera, and Rhizomucor pusillus). This assay was split into 2 multiplexed reactions and was evaluated using both samples seeded with purified nucleic acid from 42 well-characterized clinical fungal isolates and 105 archived samples (47 blood [45%], 42 bronchoalveolar lavage fluid [40%], and 16 tissue [15%]) collected from rabbit models of invasive pulmonary fungal infections.
RESULTS: Assay detection sensitivity was less than 25 copies of the target sequence per reaction for Aspergillus spp, 5 copies for Fusarium spp and Scedosporium spp, and 10 copies for the Mucorales. The assay showed quantitative linearity from 5 × 10(1) to 5 × 10(5) copies of target sequence per reaction. Sensitivities and specificities for bronchoalveolar lavage fluid, tissue, and blood samples were 0.86 and 0.99, 0.60 and 1.00, and 0.46 and 1.00, respectively.
CONCLUSIONS: Labeled primer polymerase chain reaction permits rapid, quantitative detection and differentiation of common agents of invasive fungal infection. The assay described herein shows promise for clinical implementation that may have a significant effect on the rapid diagnosis and treatment of patients' severe infections caused by these pulmonary fungal pathogens.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25357108     DOI: 10.5858/arpa.2013-0592-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  Development of new strategies for early diagnosis of mucormycosis from bench to bedside.

Authors:  Thomas J Walsh; Anna Skiada; Oliver A Cornely; Emmanuel Roilides; Ashraf Ibrahim; Theoklis Zaoutis; Andreas Groll; Olivier Lortholary; Dimitrios P Kontoyiannis; George Petrikkos
Journal:  Mycoses       Date:  2014-12       Impact factor: 4.377

2.  Evaluation of the Performance of a Multiplex Real-Time PCR Assay for the Identification of Aspergillus, Cryptococcus neoformans, and Pneumocystis jirovecii Simultaneously from Sputum in Multicenter.

Authors:  Wenjing Liu; Min Li; Yingchun Xu; Fengchao Wang; Jing Wang; Huizhu Wang; Xinmin Xu; Yajie Wang; Hongli Sun
Journal:  Infect Drug Resist       Date:  2022-10-18       Impact factor: 4.177

3.  Fungal Diseases in the 21st Century: The Near and Far Horizons.

Authors:  Arturo Casadevall
Journal:  Pathog Immun       Date:  2018-09-25

Review 4.  Diagnosis of Fusarium Infections: Approaches to Identification by the Clinical Mycology Laboratory.

Authors:  Anne D van Diepeningen; Balázs Brankovics; Jearidienne Iltes; Theo A J van der Lee; Cees Waalwijk
Journal:  Curr Fungal Infect Rep       Date:  2015

Review 5.  Rare fungal infectious agents: a lurking enemy.

Authors:  Anna Skiada; Ioannis Pavleas; Maria Drogari-Apiranthitou
Journal:  F1000Res       Date:  2017-10-31

6.  Evaluation of Two Commercial Real-Time PCR Kits for Aspergillus DNA Detection in Bronchoalveolar Lavage Fluid in Patients with Invasive Pulmonary Aspergillosis.

Authors:  Julie Denis; Faezeh Forouzanfar; Raoul Herbrecht; Elise Toussaint; Romain Kessler; Marcela Sabou; Ermanno Candolfi; Valérie Letsher-Bru
Journal:  J Mol Diagn       Date:  2018-02-19       Impact factor: 5.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.